

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 52

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

OC 02120

316 721

<p style="text-align: center;">Licensee</p> <p>1. W.A. Foote Memorial Hospital</p> <p>2. 205 N. East Avenue Jackson, MI 49201</p>	<p>In accordance with the application dated July 19, 2007, and the letter dated November 28, 2007,</p> <p>3. License number 21-00258-06</p> <hr/> <p>4. Expiration date February 28, 2011</p> <hr/> <p>5. Docket No. 030-01990 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p> <p>E. Iodine-131</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p> <p>E. Sodium-iodide</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1 Curie</p> <p>D. 1 millicuire</p> <p>E. 10 millicuries</p>
--	--	---

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-00258-06

Docket or Reference Number
030-01990

Amendment No. 52

6. Byproduct, source, and/or special nuclear material 7. Chemical and/or physical form 8. Maximum amount that licensee may possess at any one time under this license

F. Iodine-125 permitted by 10 CFR 35.400.

**F. Sealed Sources
(Medi-Physics, Inc.
or Amersham
Health Models 6711
(OncoSeed™), 6733
(EchoSeed™), 6735,
Best Medical
International, Inc.,
Model 2301, North
American Scientific,
Inc., Model
MED3631, IsoAid
L.L.C. Model IAI-
125A (Advantage™
I-125), and Bard
Brachytherapy, Inc.,
STM 1251)**

F. 2 Curies

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.
- E. Any iodine-131sodium iodide procedure for imaging and localization studies that requires a written directive in accordance with 10 CFR 35.40.
- F. Any manual brachytherapy procedure permitted by 10 CFR 35.400.**

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 205 N. East Avenue, Jackson, Michigan and **Paul Tejada Center, 1102 E. Michigan Avenue, Jackson, Michigan.**

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-00258-06

Docket or Reference Number
030-01990

Amendment No. 52

11. The Radiation Safety Officer for this license is Randall Bardwell.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Piyashbhai Chaturbhai Patel, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Sadasiva T. Reddy, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Libby Anderson, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

David A. Williamson, M.D.

10 CFR 35.100, 35.200, iodine-131 for treatment of hyperthyroidism and cardiac dysfunction, iodine-131 sodium iodide for imaging and localization studies and 31.11.

Marc B. Renner, M.D.

10 CFR 35.100, 35.200, 35.300 and 31.11.

James Heisel, M.D.

10 CFR 35.100, 35.200, and 35.300.

Renuka M. Patel, M.D.

10 CFR 35.100, 35.200, iodine-131 sodium iodide for imaging and localization studies and 31.11.

Bhaskar Shenai, M.D.

10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).

Samir Parikh, M.D.

10 CFR 35.100 and 35.200.

Mary Feng, M.D.

10 CFR 35.400.

Julie Soriano, M.D.

10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-00258-06Docket or Reference Number
030-01990

Amendment No. 52


13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated August 24, 2000 (except Quality Management Program) and **July 19, 2007**; and
- B. Letters dated July 27, 2006, June 1, 2007 and **November 28, 2007**; and
- C. Facsimile dated February 12, 2001.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

FEB 28 2008

By

William P. Reichhold
Materials Licensing Branch
Region III